BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Deferoxamine

a chelating agent, particularly in the mesylate form.

296+ PubMed studies analyzed · 3 RCTs · Evidence Score: 43.3

Research Domains

Deferoxamine has been studied across 19 research domains including 🔬 Oncology, 🫁 Liver & Detox, 🫘 Kidney, 👁️ Vision & Eye, 🔥 Metabolic. The primary research focus is 🔬 Oncology with 11% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Deferoxamine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Fluvastatin
4 shared targets
KN
5 shared targets
Flumethasone
5 shared targets
Canagliflozin
4 shared targets
deguelin
5 shared targets
beta
4 shared targets
Cerulenin
4 shared targets
Teniposide
4 shared targets
casin
4 shared targets
Deferasirox
6 shared targets
Loading evidence profile...

This evidence profile for Deferoxamine is generated deterministically from 296 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.